Blake T Langlais
Overview
Explore the profile of Blake T Langlais including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee M, Mitchell S, Basch E, Mazza G, Langlais B, Thanarajasingam G, et al.
Qual Life Res
. 2024 Nov;
34(2):495-507.
PMID: 39503942
Background: We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) items and their composite scores. Methods: We...
2.
Mead-Harvey C, Basch E, Rogak L, Langlais B, Thanarajasingam G, Ginos B, et al.
Clin Trials
. 2024 Oct;
:17407745241286065.
PMID: 39440720
Background/aims: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed to capture symptomatic adverse events from the patient perspective. We aim to describe statistical...
3.
Choi K, Spadaccio C, Ribeiro R, Langlais B, Villavicencio M, Pennington K, et al.
JTCVS Open
. 2024 Jan;
16:1020-1028.
PMID: 38204714
Objective: Innovative technology such as normothermic regional perfusion and the Organ Care System has expanded donation after circulatory death heart transplantation. We wanted to investigate the impact of donation after...
4.
Ralphs A, Anderson S, Langlais B, DCunha J, Reck Dos Santos P
Transplantation
. 2023 Dec;
108(4):1015-1020.
PMID: 38049940
Background: With increasing life expectancy, patients with HIV are more commonly acquiring other chronic diseases, such as end-stage lung disease, for which transplant may be the only effective solution. Until...
5.
Agarwal M, Liu A, Almquist D, Langlais B, Leventakos K, Yu N, et al.
Cancer
. 2023 Aug;
129(22):3546-3553.
PMID: 37548029
Background: Immune checkpoint inhibitor combined with platinum-etoposide is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The phase 3 clinical trials that led to the...
6.
Agarwal M, Liu A, Langlais B, Leventakos K, Yu N, Almquist D, et al.
Clin Lung Cancer
. 2023 Jun;
24(7):591-597.
PMID: 37365076
Background: Studies demonstrated that chemoimmunotherapy prolongs progression-free survival (PFS) and overall survival (OS) in patients with extensive-stage small-cell lung cancer (ES-SCLC) and an Eastern Cooperative Oncology Group performance status (ECOG...
7.
Kosiorek H, Scherber R, Geyer H, Verstovsek S, Langlais B, Mazza G, et al.
Br J Haematol
. 2022 Jun;
198(6):1065-1068.
PMID: 35751150
No abstract available.
8.
Langlais B, Mazza G, Kosiorek H, Palmer J, Mesa R, Dueck A
J Hematol
. 2021 Nov;
10(5):207-211.
PMID: 34804309
Background: Patients with myeloproliferative neoplasms (MPNs) suffer from chronic and progressive symptom burden. MPN trials capturing patient-reported symptoms routinely administer the MPN Symptom Assessment Form (SAF). The MPN-10 assesses 10...
9.
Mazza G, Petersen M, Ginos B, Langlais B, Heon N, Gounder M, et al.
Qual Life Res
. 2021 Oct;
31(4):1081.
PMID: 34635962
No abstract available.
10.
Mazza G, Petersen M, Ginos B, Langlais B, Heon N, Gounder M, et al.
Qual Life Res
. 2021 Aug;
31(4):1069-1080.
PMID: 34420143
Purpose: Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because patients with and without missing scores may systematically differ. We...